Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a substantial global disease burden. This study aims to elucidate the role of intestinal NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome in the gut-liver axis and provide novel insights for potential therapeutic targets. Methods Mice were fed with a methionine-choline deficient (MCD) diet for four weeks to induce MASLD models. Nlrp3fl/fl and Vil1creNlrp3fl/fl mice, with a specific knockout of NLRP3 in intestinal epithelial cells, were housed either separately or together to establish models for MASLD. Liver and intestinal tissues were collected for the assessment of hepatic steatosis, inflammation, fibrosis, and integrity of the intestinal mucosal barrier, while fecal microbiota composition was analyzed using 16S rDNA sequencing. The in vivo effects of intragastric butyrate were evaluated using Vil1creNlrp3fl/fl-MCD mice. Results Wild-type (WT)-MCD mice exhibited exacerbated hepatic steatosis and reduced intestinal NLRP3 mRNA expression compared to WT mice fed with a methionine-choline sufficient (MCS) diet, suggesting a protective role of intestinal NLRP3. The Vil1creNlrp3fl/fl-MCD vs. Nlrp3fl/fl-MCD mice exhibited elevated hepatic lipid deposition and increased expression of α-SMA. Additionally, they displayed compromised intestinal mucosal barrier function characterized by shortened villi, reduced goblet cell count, and decreased expression of Reg3a and Cldn7. The co-housed Vil1creNlrp3fl/fl-MCD with Nlrp3fl/fl-MCD mice showed a significantly ameliorated liver phenotype, characterized by reduced steatosis and fibrosis, in comparison with separately-housed Vil1creNlrp3fl/fl-MCD mice. This improvement was accompanied by an increased abundance of Faecalibaculum rodentium, a well-known butyrate producer. The in vivo administration of butyrate significantly ameliorated hepatic lipid accumulation and fibrogenesis in Vil1creNlrp3fl/fl-MCD mice. Further, a significant upregulation of activating protein-1 (AP-1) mRNA levels was observed in the liver of Vil1creNlrp3fl/fl-MCD mice, while both co-housed Vil1creNlrp3fl/fl-MCD mice and butyrate administration significantly exhibited downregulated expression of AP-1. Conclusions Deletion of NLRP3 in intestinal epithelial cells leads to a reduction in the abundance of Faecalibaculum rodentium and butyrate production, resulting in the upregulation of hepatic AP-1 expression, thereby exacerbating MASLD.

Gut Microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Interplay among IL1R1, gut microbiota, and bile acids in metabolic dysfunction‐associated steatotic liver disease: a comprehensive review

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease

Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD

Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α

Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)

Role of the Gut Microbiome in Metabolic dysfunction-Associated Steatotic Liver Disease

Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment

NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors

Innate Immunity and MASLD

Updated mechanisms of MASLD pathogenesis

Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus

NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease